[The effectiveness and toxicity of a plant secretolytic agent and its component drugs].

The 50-fold human dosage of a physiomedical drug combination (VG I) (Sinupret) and their components (VG II-VG VI) in equivalent quantity, administered 10 times within 80 h, does not lead to unexpected and undesired effects on the parameters: rate of breathing, pulse rate, red blood count. Quick-%-value and the electrolytes calcium, potassium and sodium. Differences found in single drug groups are considered to be within the range.

[Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].

Efficacy of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) and its molecule components (metabolites) of structurally similar theophylline esters and of clofibrate as standard was investigated in the artificial hyperlipidaemia of the rat. In accordance with former results etofylline clofibrate was antilipaemically active and, in contrast to similar esters and clofibrate, significantly decreased the cholesterol level. An investigation of the efficacy of its metabolites, either alone or in equivalent mixture, as well as of the standard clofibrate under fat diet demonstrated low efficacy of etofylline, but an increased activity in combination with clofibrate or clofibric acid.

[Pharmacology and toxicology of etofylline clofibrate].

1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) was investigated in acute and chronic toxicity studies, using oral application. In addition studies in reproduction toxicology and safety pharmacology were performed. Under the conditions of the experiments the following important findings were observed: In the acute toxicity studies ML 1024 showed a dose-dependent symptomatology in all three species (rat, mouse, dog) used, no late mortalities occurred.

1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (ML 1024), a new hypolipemic agent.

1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (ML 1024) was tested on acute and chronic toxicity, on teratogenesis and fetotoxicity, on blood pressure and blood flow behaviour, on hypolipemic activity and general pharmacological behaviour in a screening test using 54 parameters. Results warrant further investigation of the potential therapeutic application of ML 1024 in humans based on its superiority to the well-known antilipemic clofibrate (CPIB).